Podcast

Replay: Amol’s 10 Favourite Papers of 2015

Subscribe on iTunes

This week we are replaying our first episode of the season. Originally aired on January 11, 2016, Amol, general internal medicine resident at the University of Toronto, talk about his 10 favourite papers of 2015.

Rate us on iTunes! Follow us on Twitter @roundstable.

The Papers

1. Teixobactin, a new antibiotic:  http://www.nature.com/nature/journal/v517/n7535/full/nature14098.html

2. Modified Valsalva manoeuvre: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2815%2961485-4/abstract

3. Prednisolone or pentoxifylline for alcoholic hepatitis: http://www.nejm.org/doi/full/10.1056/NEJMoa1412278

4. Empagliflozin on cardiovascular outcomes in Type 2 Diabetes: http://www.nejm.org/doi/full/10.1056/NEJMoa1504720

5. BRIDGE – Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation: http://www.nejm.org/doi/full/10.1056/NEJMoa1501035

6. Antibiotics for community acquired pneumonia: http://www.nejm.org/doi/full/10.1056/NEJMoa1406330

7. SPRINT trial: http://www.nejm.org/doi/full/10.1056/NEJMoa1511939

8a. ESCAPE – Intra-arterial treatment for stroke: http://www.nejm.org/doi/full/10.1056/NEJMoa1414905

8b. MR. CLEAN – Intra-arterial treatment for stroke: http://www.nejm.org/doi/full/10.1056/NEJMoa1411587

9. Digoxin use in atrial fibrillation: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2961836-5/abstract

10. Corticosteroids for patients hospitalized with community-acquired pneumonia: http://annals.org/article.aspx?articleid=2424872

Music Credits (Creative Commons)

In your Robotic Heart – Nicolai Heidlas https://soundcloud.com/nicolai-heidlas/in-your-robotic-heart

Drive – Nicolai Heidlas https://soundcloud.com/nicolai-heidlas/drive-fresh-upbeat-pop-background-music

All tracks have been modified for the purposes of this podcast.

Leave a Comment

Your email address will not be published. Required fields are marked *

Republish this article

Republish this article on your website under the creative commons licence.

Learn more